Guideline Summary: Management of Diffuse Alveolar Hemorrhage with Concurrent Lupus Nephritis

Immediate Glucocorticoid Protocol

• Administer intravenous methylprednisolone 500–1000 mg/day for three consecutive days (maximum cumulative dose ≈ 3 g) as first‑line therapy for DAH with hypoxemia【1】.
• After pulse therapy, switch to weight‑based oral prednisone: < 50 kg → 50 mg/day; 50–75 kg → 60 mg/day; > 75 kg → 75 mg/day【2】.
• Taper prednisone gradually to reach 5 mg/day by weeks 19–52【2】.

Choice of Immunosuppressive Agent for Remission Induction

• Rituximab is the preferred agent over cyclophosphamide when combined with glucocorticoids for this dual‑organ emergency, because it avoids cyclophosphamide‑related nephrotoxicity while maintaining efficacy【2】 (strong recommendation).
• Rituximab dosing: 375 mg/m² intravenously weekly for four weeks【2】.
• If rituximab is unavailable, use cyclophosphamide 15 mg/kg IV on weeks 0, 2, 4, 7, 10, 13, with dose reduction of 2.5 mg/kg for age > 60 years or eGFR < 30 mL/min/1.73 m²【2】.

Lupus Nephritis‑Specific Induction Therapy (EULAR Guidelines)

• For Class III/IV lupus nephritis, prescribe mycophenolate mofetil 2–3 g/day (or equivalent mycophenolic acid)【4】 (strong recommendation).
• Low‑dose intravenous cyclophosphamide (500 mg every two weeks for six doses) is an acceptable alternative【5】.
• In patients with nephrotic‑range proteinuria and adverse prognostic factors (e.g., concurrent DAH), consider MMF + calcineurin inhibitor or high‑dose cyclophosphamide regimens【5】.

Plasma Exchange Decision‑Making (EULAR 2024)

• Strongly consider therapeutic plasma exchange when DAH is accompanied by hypoxemia and renal involvement (serum creatinine > 3.4 mg/dL or need for dialysis)【1】.
• The PEXIVAS trial (191 DAH patients, 61 with hypoxemia) showed no definitive mortality benefit and an increased risk of infection, tempering the recommendation【1】 (moderate evidence).
• Plasma exchange remains a reasonable rescue therapy in refractory cases or when anti‑GBM disease is suspected【2】.

Respiratory Support Strategy

• If mechanical ventilation is required, employ lung‑protective ventilation with tidal volumes 6–8 mL/kg predicted body weight【1】.
• Keep plateau pressure ≤ 30 cmH₂O【1】 and apply moderate PEEP of 6–8 cmH₂O【2】.
• Contraindication: avoid chest physiotherapy maneuvers (manual hyperinflation, postural drainage, percussion, forced expiration) because they can precipitate hemodynamic collapse and worsen capillary injury【1】.

Maintenance Therapy After Remission

• Continue immunosuppressive maintenance for 18 months to 4 years to prevent relapse【1】.
• Preferred maintenance agents: rituximab, azathioprine, or mycophenolate mofetil【2】.
• For lupus nephritis specifically, use MMF or azathioprine after induction together with low‑dose glucocorticoids (< 7.5 mg/day)【5】.

Monitoring Treatment Response

• Primary efficacy marker for DAH: improvement in PaO₂/FiO₂ ratio【1】.
• Serial chest imaging to document resolution of ground‑glass opacities and consolidations【1】.
• Serial hemoglobin measurements to detect ongoing pulmonary bleeding【2】.
• Aim for proteinuria ≤ 0.5–0.7 g/24 h with near‑normal renal function by 12 months for lupus nephritis【5】.
• Achieve a partial renal response (≥ 50 % reduction in proteinuria to subnephrotic levels) by 6 months【6】.

Management of Refractory Disease (within 48–72 h)

• Escalate glucocorticoid dose if no clinical improvement【2】.
• Switch between rituximab and cyclophosphamide as needed【2】.
• Re‑evaluate the diagnosis to exclude medication non‑adherence, infection, malignancy, or drug‑induced vasculitis【2】.
• Refer the patient immediately to a center with expertise in vasculitis and lupus nephritis【1】.

Adjunctive Therapies

• Continue or initiate hydroxychloroquine in all SLE patients, with regular ophthalmologic monitoring【5】 (strong recommendation).
• Avacopan 30 mg twice daily may replace glucocorticoids in patients at high risk for steroid toxicity, especially when eGFR < 30 mL/min/1.73 m²【2】 (conditional recommendation).
• High‑dose intravenous immunoglobulin can be considered in ICU patients with a particularly high infection risk【2】.

Prognostic Factors for Early Mortality (EULAR)

• Older age, severe kidney failure, greater degree of hypoxemia, and involvement of > 50 % of lung area at presentation are associated with higher early mortality in SLE‑related DAH【1】 (moderate evidence).

Common Pitfalls to Avoid

• Do not delay immunosuppressive therapy while awaiting diagnostic confirmation; start empiric treatment immediately when immune‑mediated DAH is suspected【1】.
• Do not undertreat the DAH component by using only standard lupus nephritis steroid doses; pulse methylprednisolone is essential【1】【2】.
• Do not perform chest physiotherapy in active DAH【1】.